Caliber purchases Chainlink tokens in first digital asset treasury move

Caliber (NASDAQ: CWD) completed its initial purchase of Chainlink (LINK) tokens as part of a system test transaction, the company announced. The real estate and digital asset management platform plans to fund future LINK acquisitions through its existing equity line of credit, cash reserves, and equity-based securities issuance.

The transaction represents the first implementation of Caliber's Digital Asset Treasury Strategy, which aims to accumulate LINK tokens through consistent purchases over time. The strategy seeks to generate long-term appreciation and current yield through staking.

"Caliber's Digital Asset Treasury strategy represents a disciplined, institutional approach to building a LINK position," said Chris Loeffler, Chief Executive Officer. "We have made our first purchase to test our systems and ensure we are well-positioned to manage the custody, tax, accounting, governance, and similar considerations underpinning our internal infrastructure."

Caliber stated it intends to make consistent purchases of LINK tokens to establish a material position in its treasury over time. The company described its approach as gradual, measured acquisitions designed to average into the market.

The company claims to be the first Nasdaq-listed company to publicly announce a treasury reserve policy centered on Chainlink tokens. Through this initiative, Caliber provides shareholders with mark-to-market exposure to LINK.

Caliber operates as a diversified alternative asset manager with over $2.9 billion in managed assets. The company has focused on private equity real estate investments in hospitality, multi-family residential, and industrial properties for more than 16 years before launching its digital asset treasury strategy in 2025.

The information is based on a company press release statement.

You May Also Be Interested In

• Ryman Hospitality raises ~$658M in stock offering for Orlando deal
• Adamas Trust prices $90M senior notes offering at 9.600%
• PTC wins bid for Sangamo's Fabry disease gene therapy in bankruptcy